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The human lymphocyte antigen CD38 has been shown to share sequence homology with ADP-ribosyl cyclase, the enzyme that catalyzes the 
conversion of NAD* to cyclic ADP-ribose (cADPR), a potent Ca*+-mobilizing agent. In this study COSl cells from African Green Monkey kidney 
were transiently transfected with CD38 cDNA, inducing expression of authentic CD38 on the cell surface. We demonstrate that CD38 expressed 
in this manner can convert NAD’ to cADPR in the extracellular medium as assessed by Ca” release from sea-urchin egg microsomes. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Cyclic ADP-ribose (cADPR) is a naturally occurring 
metabolite of NAD’ with potent Ca2’-mobilizing activ- 
ity. It has been implicated in regulation of the Ca2+- 
induced Ca*’ release mechanism and possesses many 
characteristics of a novel second messenger acting on a 
ryanodine-sensitive Ca2+ release channel distinct from 
the IP3 receptor [1,2]. ADP-ribosyl cyclase, the enzyme 
that synthesizes cADPR from NAD’, is ubiquitous in 
mammalian and invertebrate tissues [3-51. The cyclase 
from Ap~ysiu ovotestis has been sequenced and shows 
considerable homology with the human lymphocyte an- 
tigen CD38 [6]. CD38 is a type II integral membrane 
glycoprotein of lymphoid and myeloid cells that dis- 
plays an unusual pattern of exoression during develop- 
ment. For example, both immature and terminally dif- 
ferentiated lymphocytes within the thymus, spleen and 
lymph nodes are CD38+” whereas resting peripheral 
blood lymphocytes are mostly CD38-” [7]. The func- 
tion of CD38 remains elusive although it has been impli- 
cated in terminal differentiation of HL-60 cells [8] and 
proliferation of B-lymphocytes [9]. 
This study demonstrates that CD38 expressed on the 
surface of COS 1 cells catalyzes the conversion of 
NAD+ to cADPR and thus acts as an ADP-ribosyl 
cyclase, as suggested by homology with the Aplysia 
cyclase. Furthermore, the cyclase activity is present in 
the extracellular domain of CD38 and leads to the pro- 
duction of extracellular cADPR. 
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2.1. Materials 
Sea urchins (Echinus) were obtained from St. Davids Oceanarium, 
UK. Fluo-3 was from purchased from Calbiochem and cADPR was 
from Amersham. All other reagents were purchased from Sigma. 
2.2. Transfection of COS I cells 
COSl fibroblasts (6 x lo6 cells in 1 ml serum-free RPMI) were 
transfected by electroporation (960 pF, 750 V/cm) with CD38 cDNA 
(1Opg) cloned in pCDM8 as described previously [7]. Transfected cells 
were maintained in RPMI-1640 medium supplemented with 10% 
foetal calf serum until maximal expression was obtained (approxi- 
mately 3 days). Typically, 40% of the transfected cells were CD38”” 
as determined by immunofluorescent staining/FACSCAN analysis 
with the CD38 monoclonal antibody HIT2 [lo]. 
2.3. NAD’ incubation 
Flasks of adherent CD38-transfected COS cells were taken three 
days after transfection along with non-transfected control cells. Fol- 
lowing washing with PBS (pH 7.4), an addition of 200 PM /3-NAD’ 
in 10 ml of PBS was made to each flask. The flasks were incubated 
at 37’C and samples of the incubation medium were taken at time 
intervals up to 1 hour. These samples were immediately frozen and 
stored at -70°C. 
2.4. cADPR bioassay 
Release of microsomal Ca*’ from sea-urchin egg homogenate was 
used as a bioassay for cADPR. 5% sea-urchin egg homogenate was 
prepared as described previously [l 11. Additions of 20 ~1 of medium 
incubated with CD38+” cells and control cells were made to 500~1 of 
5% egg homogenate, and Ca*’ uptake and release was followed by 
monitoring extra-microsomal Ca*’ using fluo-3 (3 PM). Fluorescence 
intensity of fluo-3 was measured using a Perkin-Elmer LSSOB fluori- 
meter at excitation and emission wavelengths of 490 mn and 535 nm, 
respectively. Ca*’ traces were calibrated by addition of a Ca*’ stand- 
ard solution and related to a standard curve of authentic cADPR- 
induced Ca” release. 
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3. RESULTS AND DISCUSSION (a) Desensitization by cADPR 
Incubation of CD38 transfected cells in medium con- 
taining NAD’ resulted in the extracellular production 
of a Ca2’-releasing factor which we identified as 
cADPR (see below). The production of cADPR (meas- 
ured indirectly as the initial rate of Ca2’ release after 
incubation with sea-urchin microsomes) reached a max- 
imum after 15 min and then decayed to zero within 1 
h (Fig. 1). This corresponds with a maximum concen- 
tration of cADPR in the extracellular medium of 500 
nM as determined from a standard curve of cADPR 
concentration vs. Ca2’ release (data not shown). Ca2+- 
releasing activity was expressed as initial rate of 
release rather than maximal [Ca”] attained during re- 
lease which is influenced by rates of both Ca2+ release 
and resequestration. Measurement of initial rate of re- 
lease proved to be a more reproducible indication of 
Ca2’-releasing activity. No Ca2’ releasing activity was 
detected in medium incubated with non-expressing con- 
trol cells. In addition, 200 ,uM NAD’ alone was not 
sufficient to induce Ca2’ release. 
To confirm the identity of the Ca2’-releasing agent in 
the CD38 incubation medium as cADPR, the medium 
was assayed in the presence of authentic cADPR and 
IP3 (Fig. 2). The sea-urchin egg homogenate system has 
two Ca”-releasing pathways, the cADPR-sensitive 
pathway and the IP, sensitive pathway [12]. Both of 
these pathways demonstrate the phenomenon of desen- 
sitization to sequential additions of agonists. However, 
the pathways are independent and cross-desensitization 
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Fig. 1. Time course for production of Ca*’ releasing factor (cADPR) 
in the medium by CD38 transfected cells (tilled circles) or control cells 
(open circles) incubated with NAD+. The sea-urchin bioassay was 
performed as described in section 2. Initial rates of Ca2’ release were 
determined from calibrated traces of fluorescence intensity vs. time. 
The data is plotted as mean rate f S.E.M. (n = 5) and is representative 
of 3 incubations. 
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Fig. 2. Ca*+-releasing activity of CD38 incubation medium in the 
presence of authentic cADPR and IP,. Traces are of fluorescence 
intensity vs. time with an upward deflection representing Ca” 
release. (a) Desensitization to incubation medium following repeated 
addition of authentic cADPR. (b) Desensitization to authentic 
cADPR following repeated addition of incubation medium. (c) Effect 
of heparin on IP,-induced release and incubation medium-induced 
release. 
between the pathways is not seen even though release 
appears to occur from a common Ca2+ pool [1,12]. Fig. 
2a and b demonstrate desensitization of the cADPR- 
sensitive pathway of Ca2+ release following subsequent 
additions of medium from CD38+‘” cells incubated with 
NAD’ for 15 min. Pre-treatment with authentic ADPR 
also abolishes the response to medium incubated with 
CD38’” cells (instantaneous increases in fluorescence 
on additions represent contaminating Ca2+ rather than 
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Ca2’ release). However, pre-treatment with 400 ,@ml 
heparin, an IP, antagonist, had no effect on the Ca2+ 
releasing activity of the NAD+ incubation medium 
while completely blocking IP,-induced Ca2’ release. 
The results of this study demonstrate the production 
of cADPR in the extracellular medium by CD38 after 
the addition of NAD+ and thus confhm the predicted 
ADP-ribosyl cyclase activity of CD38 Fig. 1 also dem- 
onstrates a decline in the extracellular concentration of 
cADPR after a period of about 15 min suggesting the 
existence of a cADPR hydrolase activity on the cell 
surface. This co-occurrence of ADP-ribosyl cyclase ac- 
tivity and hydrolase activity has been demonstrated in 
a variety of tissues [3], and in particular on the surface 
of human erythrocytes [131. It remains a possibility that 
CD38 itself is responsible for hydrolysis of cADPR to 
ADP-ribose (ADPR). This would place CD38 in a 
growing family of bifunctional membrane-bound en- 
zymes that possess both cyclase and hydrolase activity 
catalyzing the net conversion of NAD’ to ADPR via 
cADPR [13,14]. These enzymes have previously been 
classified as NAD glycohydrolases (NADase), a group 
of enzymes catalyzing the hydrolysis of NAD+ to 
ADPR whose function has remained elusive [15]. In- 
deed, a previous study has attributed a retinoic acid- 
induced NADase activity on the surface of HL-60 cells 
to the CD38 antigen [8]. 
The extracellular location of the CD38 catalytic do- 
main is particularly intriguing. A role for extracellular 
cADPR may be envisaged or alternatively, activation 
may lead to internalization of CD38 and intracellular 
production of cADPR. In either case, this study pre- 
sents the possibility that CD38 functions through regu- 
lating the production and hydrolysis of cADPR. Associ- 
ation of cyclase and hydrolase activity on a single 
enzyme would provide a mechanism for tight regula- 
tion of [cADPR], a prerequisite for what is perhaps 
a novel second messenger. The precedent for con- 
certed regulation of a bifunctional enzyme has 
been set by 6-phosphofructo-2-kinase/fructose-2,6-bis- 
phosphatase (PFIUFBP), an enzyme catalyzing both 
the synthesis and hydrolysis of fructose-2,6-bis- 
phophate that is reciprocally regulated by CAMP-de- 
pendent phosphorylation [16]. Interestingly, it has re- 
cently been suggested that ADP-ribosyl cyclase from 
sea-urchin eggs is regulated by cGMP-dependent 
phophorylation [17]. In addition, the catalytic activity 
of cell-surface CD38 may potentially be regulated by 
binding of extracellular factors. We are currently ex- 
ploring this possibility. 
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